HLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference

About this update from Hls Therapeutics, Inc.

[{"type":"text","content":"\n\n\n\nHLS Therapeutics to Present at the Jefferies Virtual Healthcare Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, June 1, 2020\n\n\n\nTORONTO, June 1, 2020 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday June 3, 2020 at 9:00 a.m. Eastern Daylight Time.\nAn audio webcast of Mr. Gubitz's presentation will be available at: http://hlstherapeutics.investorroom.com/events or http://wsw.com/webcast/jeff126/hls.to/   \nABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information, please visit: www.hlstherapeutics.com \nSOURCE HLS Therapeutics Inc.\n\n\n\n View original content: http://www.newswire.ca/en/releases/archive/June2020/01/c8271.html\n\n\n\n\nHLS CONTACT INFORMATION: Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, [email protected]; Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, [email protected] CNW Group 2020","length":3546,"tagName":"div"}]

More updates from Hls Therapeutics, Inc.